Maksay G, Tegyey Z, Simonyi M
Central Research Institute for Chemistry, Hungarian Academy of Sciences, Budapest.
Mol Pharmacol. 1991 Jun;39(6):725-32.
3-Acyloxy-, 3-methoxy-, and 3-alkyl-substituted derivatives of the benzodiazepine (BZ) agonist desmethyl-diazepam (DMD) were resolved, and the stereochemical properties of binding to central BZ receptors were investigated in synaptosomal membrane preparations of rat brain. Decreasing potency and stereoselectivity of 3-methyl, 3-ethyl, and 3-isopropyl derivatives in displacement of [3H]diazepam binding can be attributed to differential susceptibilities for steric hindrance of 3-axial versus 3-equatorial substituents of the binding conformation M. Chirality in the alpha-methyl-beta-phenyl-propionic acyl moiety of oxazepam, the 3-OH-derivative of DMD, was noncritical in binding, whereas the beta-phenyl substituent selectively increased the binding of the 3S-stereoisomer. Changing the pH from 7.4 to 5.6 significantly increased the IC50 of (3R)-oxazepam acetate but not those of (3R)-methyl-DMD and diazepam. Binding data led to a steric model of the BZ binding site with the postulation of an additional hydrogen-bond-donating moiety, probably histidine in the "ceiling" of the receptor cavity, that binds the 3-carbonyloxy groups and hinders the 3-alkyl ones. In vitro efficacies of 3-substituted BZs were estimated by allosteric binding interactions within the gamma-aminobutyric acidA (GABAA) receptor-ionophore complex. Non-equilibrium enhancement of t-butyl-bicyclophosphoro[35S]thionate binding by the BZ agonist oxazepam was stereoselectively antagonized by (3S)-oxazepam-(S)-alpha-methyl-beta-phenyl-propionate, suggesting a mixed agonist-antagonist character. GABA enhanced the [3H]diazepam-displacing potencies of the 3S-enantiomers of the acetate, hemisuccinate, and (S)-alpha-methyl-beta-phenyl-propionate esters of oxazepam by a factor of about 1.5-1.6, whereas the GABA shifts for 3R-esters were about 1.2. UV affinity labeling with flunitrazepam resulted in a significantly smaller decrease in the displacing potency of (3R)-oxazepam acetate than in that of the 3S-enantiomer. GABA shifts of successively 3-methylated DMD derivatives were also compared. The GABA shifts of DMD and its (3S)-methyl and 3,3-dimethyl derivatives were all characteristic of full agonists (2.4-2.7), whereas that of (3R)-methyl-DMD was 1.5. The 3-methoxy enantiomers of DMD displayed stereoselectivity and GABA shift values intermediate between those of 3-methyl and 3-acetoxy derivatives. These allosteric interactions suggest that 3-carbonyloxy derivatives in general, as well as (3R)-BZ enantiomers bound with axial 3-alkyl and 3-alkyloxy groups, decrease the agonist efficacies of 1,4-BZs to modulate the GABAA receptor complex.
对苯二氮䓬(BZ)激动剂去甲西泮(DMD)的3 - 酰氧基、3 - 甲氧基和3 - 烷基取代衍生物进行了拆分,并在大鼠脑突触体膜制剂中研究了其与中枢BZ受体结合的立体化学性质。3 - 甲基、3 - 乙基和3 - 异丙基衍生物在取代[³H]地西泮结合时效力和立体选择性降低,这可归因于结合构象M的3 - 轴向与3 - 赤道取代基对空间位阻的不同敏感性。奥沙西泮(DMD的3 - OH衍生物)的α - 甲基 - β - 苯基 - 丙酸酰基部分的手性在结合中并不关键,而β - 苯基取代基选择性地增加了3S - 立体异构体的结合。将pH从7.4变为5.6显著增加了(3R) - 奥沙西泮乙酸酯的IC50,但未增加(3R) - 甲基 - DMD和地西泮的IC50。结合数据得出了BZ结合位点的空间模型,推测在受体腔“顶部”有一个额外的氢键供体部分,可能是组氨酸,它与3 - 羰氧基结合并阻碍3 - 烷基基团。通过γ - 氨基丁酸A(GABAA)受体 - 离子载体复合物内的变构结合相互作用评估了3 - 取代BZs的体外效力。BZ激动剂奥沙西泮对叔丁基 - 双环磷[³⁵S]硫代酸盐结合的非平衡增强被(3S) - 奥沙西泮 - (S) - α - 甲基 - β - 苯基 - 丙酸酯立体选择性拮抗,表明具有混合激动剂 - 拮抗剂特性。GABA使奥沙西泮乙酸酯、半琥珀酸酯和(S) - α - 甲基 - β - 苯基 - 丙酸酯的3S - 对映体取代[³H]地西泮的效力提高约1.5 - 1.6倍,而3R - 酯的GABA位移约为1.2。用氟硝西泮进行紫外亲和标记导致(3R) - 奥沙西泮乙酸酯取代效力的降低明显小于3S - 对映体。还比较了连续3 - 甲基化DMD衍生物的GABA位移。DMD及其(3S) - 甲基和3,3 - 二甲基衍生物的GABA位移均为完全激动剂的特征(2.4 - 2.7),而(3R) - 甲基 - DMD的为1.5。DMD的3 - 甲氧基对映体表现出立体选择性,GABA位移值介于3 - 甲基和3 - 乙酰氧基衍生物之间。这些变构相互作用表明,一般来说,3 - 羰氧基衍生物以及与轴向3 - 烷基和3 - 烷氧基结合的(3R) - BZ对映体降低了1,4 - BZs调节GABAA受体复合物的激动剂效力。